Oral Medication Approved for MS in Canada

.

Oral Medication Approved for MS in Canada

Multiple Sclerosis treatment is bound to revolutionize in Canada as drug-maker Novartis Pharmaceutical Canada Inc. announced on Thursday that the first oral medicine for the condition has been approved for use by some patients in the country. The medication will basically help in providing treatment for the symptoms of MS.

The medicine has been named Gilenya and will be available for sale from the 1st of April at pharmaceutical stores across the nation. The medicine will be available for people who have tried another treatment for the condition with poor results.

The chemical name for Gilenya is fingolimod and it will be used for people with the relapsing-remitting form of the condition. According to the figures available, the disease ends up affecting an astounding 75,000 Canadians. People with this variety of the condition are likely to experience new symptoms with severity of older symptoms worsening.

Gilenya will help in reducing flare-ups of people suffering from multiple sclerosis and will also help in reducing the rate of progress. Each capsule of Gilenya contains 0.5 milligrams of the drug and is the most convenient treatment for MS in Canada.

Talking about the development, a Neurologist from Toronto, Dr. Daniel Selchan, said: "The approval of Gilenya is a significant milestone for the Canadian MS community".


Latest News

Amazon Fire TV Stick will offer stiff competition to Neflix and Hulu Plus
New Chromebook buyers get 1TB free Google Drive storage space
China Adds Fresh Stimulus to Pep Up Growth
End of Harvest Season Results in Job Losses in Farming Sector
WalletHub Released a List of Best Deals on Black Friday
Massachusetts Regulators to Decide on Issue of Limiting time and Money for Gambl
More People Are Expected to Travel by Road during the Thanksgiving Holiday, due
Sotheby’s CEO, William Ruprecht to Step Down
Alibaba does well in the American Bond Market
Target's Holiday Season Sales Expected to Fetch Good Results
Uber’s New York Office Executive Investigated for Spying on Journalist
China’s Factory Gauge in November Dropped to a Six Month Low